Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI0618 for episodic migraine
2024-512904-21-00Phase 2Authorised
- Sponsor
- AbbVie Inc.
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial in migraine comparing MEDI0618 with Placebo (2 arms). Planned start Nov 2024; status: authorised.
02
Drugs
MEDI0618
03
Conditions
migraine
Beyond the preview
Go deeper on 2024-512904-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512904-21-00.